*DJ Roche: Investigational Antibody Cocktail of Casirivimab and Imdevimab Reduced Hospitalisation in COVID-19 Patients
(MORE TO FOLLOW) Dow Jones Newswires
March 23, 2021 02:06 ET (06:06 GMT)
*DJ Roche: Positive Results Are From New Phase 3 Data From Trial Assessing COVID-19 Treatment in Infected Non-Hospitalised Patients
(MORE TO FOLLOW) Dow Jones Newswires
March 23, 2021 02:07 ET (06:07 GMT)
*DJ Roche: Treatment Also Reduced Death by 70% in Non-Hospitalised Patients With COVID-19
(MORE TO FOLLOW) Dow Jones Newswires
March 23, 2021 02:08 ET (06:08 GMT)
*DJ Roche: Treatment Also Significantly Shortened the Duration of Symptoms by Four Days
(MORE TO FOLLOW) Dow Jones Newswires
March 23, 2021 02:09 ET (06:09 GMT)
*DJ Roche: Phase III Outcomes Trial Met Its Primary Endpoint
(MORE TO FOLLOW) Dow Jones Newswires
March 23, 2021 02:10 ET (06:10 GMT)
*DJ Roche: Casirivimab and Imdevimab Also Met All Key Secondary Endpoints in the Phase III REGN-COV 2067 Trial
(MORE TO FOLLOW) Dow Jones Newswires
March 23, 2021 02:10 ET (06:10 GMT)
*DJ Roche: Endpoints Include Ability to Reduce Symptom Duration From 14 to 10 Days
(MORE TO FOLLOW) Dow Jones Newswires
March 23, 2021 02:11 ET (06:11 GMT)
DJ Roche Covid-19 Antibody Trial Meets Primary Endpoint
By Cecilia Butini
Roche Holding AG said Tuesday that a phase-3 clinical trial assessing an antibody cocktail to treat Covid-19 in non-hospitalized patients met its primary endpoint.
The Swiss pharma major said its investigational antibody cocktail of casirivimab and imdevimab reduced the risk of hospitalization or death by 70% compared with a placebo.
The drugs also met the secondary endpoints of the study, which included the ability to reduce symptom duration from 14 to 10 days, the company said.
It added that it would soon share results from the trial with regulatory authorities and from another phase 2/3 study on the use of the same drugs in hospitalized patients.
On Feb 26, the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion supporting use of the cocktail for the treatment of Covid-19 infections.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
March 23, 2021 02:20 ET (06:20 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.